Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer

Gefitinib (‘Iressa’, ZD1839) is an orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has demonstrated antitumour activity and favourable tolerability in Phase II studies. We investigated whether EGFR expression levels could predict for response to gefitinib in pati...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Parra, H S, Cavina, R, Latteri, F, Zucali, P A, Campagnoli, E, Morenghi, E, Grimaldi, G C, Roncalli, M, Santoro, A
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group 2004
Pynciau:
Clinical
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC2409824/
https://ncbi.nlm.nih.gov/pubmed/15187994
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601923
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg